LYRA News and Press, Lyra Therapeutics Inc. From 10/06/25

Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

2025-08-12 18:45:13 ET Lyra Therapeutics, Inc. (LYRA) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.95%. The average open to low on the day of earnings was -2.79%. The average open t...

2025-08-12 18:40:10 ET Lyra Therapeutics, Inc. (LYRA) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in LYRA stock price following earnings has averaged ±1.25% , with a median of 1.10%. ...

2025-08-12 16:46:14 ET More on Lyra Therapeutics Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22% Microcap...

– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) – – Financing ann...

2025-07-22 17:46:25 ET More on Lyra Therapeutics Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22% Microcap...

2025-06-27 08:42:31 ET Lyra Therapeutics ( NASDAQ: LYRA ) announced that it will raise capital through a registered direct offering and a concurrent private placement, which involves selling 423,372 common shares (or pre-funded warrants) and warrants to purchase up to 846,744 co...

WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), ...

2025-06-16 16:14:20 ET Thesis Overview Lyra therapeutics ( LYRA ) is developing corticosteroid-eluting implants for treatment of chronic rhinosinusitis; LYR-210 for patients without prior surgery and LYR-220 for patients with prior ethmoid sinus surgery. A single therapy (easily...